Roivant’s brepocitinib meets primary endpoint in uveitis trials
In
Investing.comBy Investing.com10/21/2026, 11:04:36 AM
EXECUTIVE SUMMARY
Roivant’s brepocitinib meets primary endpoint in uveitis trials....
Key Takeaways
- Roivant’s brepocitinib meets primary endpoint in uveitis trials.
Read Complete Original Article
Published originally on Investing.com
Related News
finance4 minutes ago
Digital Gold's Path to US$700bn Market Expansion - Investing News Network
Digital Gold's Path to US$700bn Market Expansion Investing News Network
finance13 minutes ago
Strive announces first dividends for SATS preferred stock at 15 percent annual rate
Strive announces first dividends for SATS preferred stock at 15 percent annual rate....
finance14 minutes ago
INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar
INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar....
finance14 minutes ago
Why is Applied Digital stock rallying today?
Why is Applied Digital stock rallying today?....
Multikhabar App
All Information In One Place
Real-time headlines from trusted sources. Get the app now — stay updated, inspired, and ahead with breaking news!